BMS Expands CAR-T Therapy Capabilities with Strategic $380 Million Investment in Cellares

BMS, Bristol Myers Squibb, Cellares, CAR-T therapy, cell therapy, cancer treatment, biotechnology, investment, capacity expansion, manufacturing, automation.